Imunon, Inc. Deferred State and Local Income Tax Expense (Benefit)
Imunon, Inc. (IMNN) reported Deferred State and Local Income Tax Expense (Benefit) of -$1.28 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2025-02-27
- Imunon, Inc. deferred state and local income tax expense (benefit) for fiscal 2023 was -$1.28M.
- Imunon, Inc. deferred state and local income tax expense (benefit) for fiscal 2022 was -$1.57M.
- Imunon, Inc. deferred state and local income tax expense (benefit) for fiscal 2021 was -$1.38M.
- Imunon, Inc. deferred state and local income tax expense (benefit) for fiscal 2020 was -$1.85M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month | Deferred State and Local Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2023-12-31 | -$1.28M 10-K · filed 2025-02-27 | |
| 2022-12-31 | -$1.57M 10-K · filed 2024-03-28 | |
| 2021-12-31 | -$1.38M 10-K · filed 2023-03-30 | |
| 2020-12-31 | -$1.85M 10-K · filed 2022-03-31 | |
| 2019-12-31 | -$1.82M 10-K · filed 2021-03-19 | -$1.82M 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |